Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Methods of predicting ancestral virus sequences and uses thereof
US10119125B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10119125-B2 |
| Application number | US-201715633292-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 26, 2017 |
| Priority date | Oct 11, 2013 |
| Publication date | Nov 6, 2018 |
| Grant date | Nov 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
First claim
Opening claim text (preview).
What is claimed is: 1. An adeno-associated virus (AAV) capsid polypeptide having the amino acid sequence shown in SEQ ID NO: 5. 2. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide: exhibits a lower seroprevalence than does an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide exhibits about the same or a lower seroprevalence than does an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide; and/or is neutralized to a lesser extent by human serum than is an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum than is an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide. 3. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide is purified. 4. The AAV capsid polypeptide of claim 1 , encoded by the nucleic acid sequence shown in SEQ ID NO: 6. 5. A nucleic acid molecule encoding an adeno-associated virus (AAV) capsid polypeptide having the nucleic acid sequence shown in SEQ ID NO: 6. 6. A vector comprising the nucleic acid molecule of claim 5 . 7. An isolated host cell comprising the vector of claim 6 . 8. A purified virus particle comprising the AAV capsid polypeptide of claim 1 . 9. The purified virus particle of claim 8 , further comprising a transgene.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunostimulants · CPC title
Ophthalmic agents · CPC title
against growth factors {; against growth regulators} · CPC title
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10119125B2 cover?
- Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
- Who is the assignee on this patent?
- Massachusetts Eye & Ear Infirmary, Schepens Eye Res Inst
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).